Skip to main content
. 2022 Apr 19;10(5):e616. doi: 10.1002/iid3.616

Figure 2.

Figure 2

(A, B) M‐MDSCs and G‐MDSCs in CLL patients compared to healthy controls. (C, D) M‐MDSCs and G‐MDSCs in DLBCL patients compared to healthy controls. (E, F) M‐MDSCs and G‐MDSCs in HGBL patients compared to healthy controls. (G, H) M‐MDSCs and G‐MDSCs in MCL patients compared to healthy controls. (I, J) M‐MDSCs and G‐MDSCs in MCL patients compared to healthy controls. CLL, chronic lymphocytic leukemia; DLBDL, diffuse large B‐cell lymphoma; G‐MDSC, granulocyte myeloid‐derived suppressor cells; HGBL, high‐grade B‐cell lymphoma; MCL, Mantle‐cell lymphoma; MDSC, myeloid‐derived suppressor cells; M‐MDSC, monocyte MDSC; MZL, marginal zone lymphoma; PCNSL, primary central nervous system lymphoma. *p < .05, **p < .01, ***p < .001, ****p < .0001, ns p ≥ .05.